Team II Endogenous Neuroprotection in Neurodegenerative Diseases, INSERM U. 710, 34095 Montpellier Cedex 5, France.
Pharmacol Ther. 2009 Nov;124(2):195-206. doi: 10.1016/j.pharmthera.2009.07.001. Epub 2009 Jul 18.
Originally considered an enigmatic protein, the sigma-1 receptor has recently been identified as a unique ligand-regulated molecular chaperone in the endoplasmic reticulum of cells. This discovery causes us to look back at the many proposed roles of this receptor, even before its molecular function was identified, in many diseases such as methamphetamine or cocaine addiction, amnesia, pain, depression, Alzheimer's disease, stroke, retinal neuroprotection, HIV infection, and cancer. In this review, we examine the reports that have clearly shown an agonist-antagonist relationship regarding sigma-1 receptors in models of those diseases and also review the relatively known mechanisms of action of sigma-1 receptors in an attempt to spur the speculation of readers on how the sigma-1 receptor at the endoplasmic reticulum might relate to so many diseases. We found that the most prominent action of sigma-1 receptors in biological systems including cell lines, primary cultures, and animals is the regulation and modulation of voltage-regulated and ligand-gated ion channels, including Ca(2+)-, K(+)-, Na(+), Cl(-), and SK channels, and NMDA and IP3 receptors. We found that the final output of the action of sigma-1 receptor agonists is to inhibit all above-mentioned voltage-gated ion channels, while they potentiate ligand-gated channels. The inhibition or potentiation induced by agonists is blocked by sigma-1 receptor antagonists. Other mechanisms of action of sigma-1 receptors, and to some extent those of sigma-2 receptors, were also considered. We conclude that the sigma-1 and sigma-2 receptors represent potential fruitful targets for therapeutic developments in combating many human diseases.
最初被认为是一种神秘的蛋白质,σ-1 受体最近被鉴定为细胞内质网中一种独特的配体调节分子伴侣。这一发现促使我们回顾该受体的许多先前提出的作用,甚至在其分子功能被确定之前,就在许多疾病中,如甲基苯丙胺或可卡因成瘾、健忘症、疼痛、抑郁、阿尔茨海默病、中风、视网膜神经保护、HIV 感染和癌症。在这篇综述中,我们检查了那些在这些疾病的模型中明确显示 σ-1 受体激动剂-拮抗剂关系的报告,还回顾了相对已知的 σ-1 受体作用机制,试图激发读者对内质网中的 σ-1 受体如何与如此多的疾病相关的猜测。我们发现,σ-1 受体在包括细胞系、原代培养物和动物在内的生物系统中的最突出作用是调节和调制电压门控和配体门控离子通道,包括 Ca(2+)、K(+)、Na(+)、Cl(-)和 SK 通道,以及 NMDA 和 IP3 受体。我们发现,σ-1 受体激动剂作用的最终结果是抑制所有上述电压门控离子通道,同时增强配体门控通道。σ-1 受体拮抗剂可阻断激动剂诱导的抑制或增强作用。还考虑了 σ-1 受体的其他作用机制,在某种程度上也考虑了 σ-2 受体的作用机制。我们的结论是,σ-1 和 σ-2 受体代表了在对抗许多人类疾病的治疗开发中具有潜在价值的靶点。